Men's Health Women's Health Senior's Health Antioxidants Sports Nutrition Diet & Weight Loss Vitamins & Minerals Herbs Specialty Supplements Targeted Supplements Spa Products Anti-Aging Basics Body Systems Body Structure Book Store Pet Health My Recommendation My Favorite Articles Our Most Popular Specials Bargain Basement Brands

MSM

Health News Archive 125 - Multiple Sclerosis
<<back to structure/function index

Glucosamine Improves Symptoms in Mouse Model of Multiple Sclerosis

Using a mouse model of Multiple Sclerosis (MS) in an animal study, Glucosamine dramatically delayed the onset of symptoms and improved the animal's ability to move and walk.

Lysaker, Norway, December 6, 2005. In a scientific article, published in the Journal of Immunology on December 1, 2005 the researchers investigated the therapeutic effect of Experimental Autoimmune Encephalomyelitis (EAE), an animal model of MS. It was demonstrated that oral or intravenous administration of glucosamine significantly reduced acute EAE, with reduced inflammation of the Central Nervous System (CNS).

More than 300,000 patients in the USA, and 300,000 patients in the 5 largest European countries, suffer from Multiple Sclerosis. Existing MS drugs are given by injections, have unfavorable safety profiles and have a yearly treatment cost in the range of $7,500 - $15,000. Should oral glucosamine prove to be effective also in humans, either alone or in combination with other disease-modifying immunotherapies, it could mean a step forward in the management of MS.

"This study indicates a very interesting potential for a new application of glucosamine", says Øyvind Brekke, CEO of Navamedic. "Although clinical trials on humans are required before it can be concluded on clinical effectiveness in MS, these findings suggest the future may bring additional indications for glucosamine."